Test Price
1,800 AED✅ Home Collection Available
Duchenne / Becker Muscular Dystrophy (DMD / BMD) Gene Mutation Test in UAE | 1800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary & UAE Patient Guarantee
- Diagnostic Precision: 99.9% analytical sensitivity and specificity via MLPA technology, processed in an ISO 9001:2015 accredited facility (Cert: INT/EGQ/2509DA/3139).
- Premium Home Collection: VIP mobile phlebotomy with validated cold‑chain logistics (8 AM – 11 PM daily). No clinic visit required.
- Clinical Guidance: Post‑test telephonic interpretation session with a DHA‑licensed Consultant Medical Genetics to explain your child’s or your results in context.
- Insurance & Billing: Direct insurance verification and pre‑approval via WhatsApp (+971 54 548 8731) – we handle the paperwork.
Test Overview & Methodology
The Duchenne / Becker Muscular Dystrophy (DMD/BMD) gene mutation test detects deletions and duplications in the dystrophin gene using Multiplex Ligation‑dependent Probe Amplification (MLPA) — the gold‑standard first‑tier assay endorsed by DHA neuromuscular guidelines. This blood‑based test identifies the genetic cause in approximately 70‑80% of affected males, guiding precise diagnosis, carrier screening, and future therapeutic eligibility.
| Feature | Our DHA‑Approved Test | Closest Alternative (Generic Lab) |
|---|---|---|
| Methodology | MLPA (Multiplex Ligation‑dependent Probe Amplification) – full deletion/duplication coverage of all 79 exons | MLPA or limited NGS panel, no DHA‑specific pre‑analytic validation |
| Diagnostic Sensitivity | 99.9% analytical specificity; includes reflex confirmatory analysis if needed | Often 95-98% without internal quality cross‑checks |
| Turnaround Time | 3 weeks (21 calendar days) from sample arrival | 4‑6 weeks |
| Price (AED) | 1,800 AED – inclusive of home collection, clinical summary, and insurance handling | 2,000‑2,500 AED (hidden fees for forms/reports) |
| UAE Regulatory Compliance | Full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning ICT in health fields. | Often missing documented UAE genetic consent and pediatric protection protocols |
| Post‑Test Support | Free telephonic clinical guidance with a DHA‑licensed Consultant Medical Genetics | Result only; no genetic counselling included |
Physician Insight & Safety Protocols
A Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
“This MLPA test reliably identifies large deletions and duplications that account for the majority of Duchenne and Becker muscular dystrophy cases; however, a normal result does not exclude point mutations or rare deep intronic variants. I strongly recommend that every result be interpreted in the context of a complete neuromuscular examination, creatine kinase levels, and family history. A genetic diagnosis is a powerful step — it opens the door to anticipatory care, clinical trials, and family planning, but it must be integrated thoughtfully into your child’s overall healthcare journey.”
Advisory Notice on Medication Continuity
⚠️ Medication Notice
Do not discontinue or adjust any prescribed medication (e.g., corticosteroids, cardiac medications) without explicit instruction from your treating physician. Abrupt medication changes may precipitate life‑threatening complications in muscular dystrophy.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion criteria: Acute febrile illness, blood transfusion within the last 4 weeks, or active systemic infection. Home phlebotomists are trained to defer collection if unsafe.
- Pediatric/minor consent: In strict accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability, a parent or legal guardian must provide written consent and complete Form 20.
- Red flags requiring ER evaluation (not this test): Sudden loss of ambulation, severe respiratory distress, choking, cardiac arrhythmia, or loss of consciousness. This genetic test does not address acute neuromuscular emergencies.
- Data privacy: Your genomic data is protected under Federal Decree‑Law No. 45 of 2021 (PDPL) and stored exclusively on DHA‑compliant encrypted servers. It will never be shared without your written authorization.
Patient FAQ & Clinical Guidance
1. What is the Duchenne/Becker gene mutation blood test?
Answer: This test uses MLPA technology to detect deletions and duplications in the dystrophin gene, which are responsible for Duchenne and Becker muscular dystrophy. It is performed on a standard blood sample and does not require any special preparation.
2. How long do results take and how will I receive them?
Answer: Results are finalized within 21 calendar days (3 weeks) from the day the sample reaches our ISO‑accredited laboratory. A secure, encrypted PDF report is sent via email, and a DHA‑licensed Consultant Medical Genetics schedules a phone consultation to explain the findings, answer questions, and recommend next steps at no extra cost.
3. Will my health insurance cover this genetic test?
Answer: Most UAE insurance plans cover this medically necessary genetic test when a physician referral and completed Form 20 are provided. Send your insurance card and Emirates ID via WhatsApp to +971 54 548 8731, and our team will verify direct billing eligibility within 2 hours, saving you upfront payment.
UAE Regulatory & Data Privacy Adherence
Your genetic data is handled in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures and patient consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is a DHA‑licensed facility (License No. 1143) and maintains ISO 9001:2015 certification. Your genomic information is stored on encrypted servers within the UAE and is never shared without explicit written consent.
Clinical & Logistical Metadata
| Test Name | Duchenne / Becker Muscular Dystrophy (DMD / BMD) Gene Mutation Test |
| Price (AED) | 1,800 AED |
| Turnaround Time | 21 calendar days (3 weeks) |
| Sample Type / Matrix | Peripheral whole blood (3-5 mL in EDTA tube) |
| Methodology Used | Multiplex Ligation‑dependent Probe Amplification (MLPA) |
| ICD-10-CM Code | G71.0 (Duchenne / Becker muscular dystrophy) |
| LOINC Code | 21655-8 (Dystrophin gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians